Logo image of VKTX

VIKING THERAPEUTICS INC (VKTX) Stock Fundamental Analysis

NASDAQ:VKTX - Nasdaq - US92686J1060 - Common Stock - Currency: USD

29.49  +0.13 (+0.44%)

After market: 29.4899 0 (0%)

Fundamental Rating

3

Taking everything into account, VKTX scores 3 out of 10 in our fundamental rating. VKTX was compared to 563 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for VKTX as it has an excellent financial health rating, but there are worries on the profitability. VKTX does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

In the past year VKTX has reported negative net income.
VKTX had a negative operating cash flow in the past year.
In the past 5 years VKTX always reported negative net income.
In the past 5 years VKTX always reported negative operating cash flow.
VKTX Yearly Net Income VS EBIT VS OCF VS FCFVKTX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50M -100M -150M

1.2 Ratios

With an excellent Return On Assets value of -14.79%, VKTX belongs to the best of the industry, outperforming 82.95% of the companies in the same industry.
VKTX has a Return On Equity of -15.14%. This is amongst the best in the industry. VKTX outperforms 88.45% of its industry peers.
Industry RankSector Rank
ROA -14.79%
ROE -15.14%
ROIC N/A
ROA(3y)-25.43%
ROA(5y)-23.56%
ROE(3y)-28.18%
ROE(5y)-25.59%
ROIC(3y)N/A
ROIC(5y)N/A
VKTX Yearly ROA, ROE, ROICVKTX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50 -100 -150 -200 -250

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for VKTX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
VKTX Yearly Profit, Operating, Gross MarginsVKTX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024

More info and screens

8

2. Health

2.1 Basic Checks

The number of shares outstanding for VKTX has been increased compared to 1 year ago.
VKTX has more shares outstanding than it did 5 years ago.
VKTX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
VKTX Yearly Shares OutstandingVKTX Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
VKTX Yearly Total Debt VS Total AssetsVKTX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M

2.2 Solvency

An Altman-Z score of 98.21 indicates that VKTX is not in any danger for bankruptcy at the moment.
VKTX has a Altman-Z score of 98.21. This is amongst the best in the industry. VKTX outperforms 99.47% of its industry peers.
There is no outstanding debt for VKTX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 98.21
ROIC/WACCN/A
WACCN/A
VKTX Yearly LT Debt VS Equity VS FCFVKTX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M 400M 600M 800M

2.3 Liquidity

A Current Ratio of 44.25 indicates that VKTX has no problem at all paying its short term obligations.
VKTX's Current ratio of 44.25 is amongst the best of the industry. VKTX outperforms 99.47% of its industry peers.
A Quick Ratio of 44.25 indicates that VKTX has no problem at all paying its short term obligations.
With an excellent Quick ratio value of 44.25, VKTX belongs to the best of the industry, outperforming 99.47% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 44.25
Quick Ratio 44.25
VKTX Yearly Current Assets VS Current LiabilitesVKTX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M

More info and screens

1

3. Growth

3.1 Past

VKTX shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -23.66%.
EPS 1Y (TTM)-23.66%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-57.69%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, VKTX will show a quite strong growth in Earnings Per Share. The EPS will grow by 14.96% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-60.33%
EPS Next 2Y-46.81%
EPS Next 3Y-35.89%
EPS Next 5Y14.96%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
VKTX Yearly Revenue VS EstimatesVKTX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2025 2026 2027 2028 2029 2030 2031 2032 1B 2B 3B
VKTX Yearly EPS VS EstimatesVKTX Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 5 10 15

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

VKTX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for VKTX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
VKTX Price Earnings VS Forward Price EarningsVKTX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
VKTX Per share dataVKTX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 6

4.3 Compensation for Growth

A cheap valuation may be justified as VKTX's earnings are expected to decrease with -35.89% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-46.81%
EPS Next 3Y-35.89%

More info and screens

0

5. Dividend

5.1 Amount

VKTX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

VIKING THERAPEUTICS INC

NASDAQ:VKTX (5/5/2025, 8:00:02 PM)

After market: 29.4899 0 (0%)

29.49

+0.13 (+0.44%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)04-23 2025-04-23/amc
Earnings (Next)07-22 2025-07-22/amc
Inst Owners75%
Inst Owner Change-1.77%
Ins Owners2.8%
Ins Owner Change1.12%
Market Cap3.31B
Analysts84.8
Price Target95 (222.14%)
Short Float %23.38%
Short Ratio5.43
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-18.8%
Min EPS beat(2)-23.91%
Max EPS beat(2)-13.7%
EPS beat(4)2
Avg EPS beat(4)1.03%
Min EPS beat(4)-23.91%
Max EPS beat(4)27.38%
EPS beat(8)5
Avg EPS beat(8)1.99%
EPS beat(12)6
Avg EPS beat(12)0.7%
EPS beat(16)9
Avg EPS beat(16)2.45%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-8.45%
PT rev (3m)-17.86%
EPS NQ rev (1m)-18.69%
EPS NQ rev (3m)-33.45%
EPS NY rev (1m)1.48%
EPS NY rev (3m)-6.51%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-5.9%
Revenue NY rev (3m)-29.41%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 3.91
P/tB 3.91
EV/EBITDA N/A
EPS(TTM)-1.15
EYN/A
EPS(NY)-2.16
Fwd EYN/A
FCF(TTM)-1.19
FCFYN/A
OCF(TTM)-1.19
OCFYN/A
SpS0
BVpS7.54
TBVpS7.54
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -14.79%
ROE -15.14%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-25.43%
ROA(5y)-23.56%
ROE(3y)-28.18%
ROE(5y)-25.59%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 44.25
Quick Ratio 44.25
Altman-Z 98.21
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-23.66%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-57.69%
EPS Next Y-60.33%
EPS Next 2Y-46.81%
EPS Next 3Y-35.89%
EPS Next 5Y14.96%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-50.67%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-33.97%
EBIT Next 3Y-33.79%
EBIT Next 5Y-17.46%
FCF growth 1Y-114.34%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-114.34%
OCF growth 3YN/A
OCF growth 5YN/A